Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Hexarelin vs Sermorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Hexarelin and Sermorelin share the gh-secretagogue class and carry roughly equivalent evidence (Phase 2 (not approved) / Discontinued (FDA approval 1990; US withdrawal 2008)). On the catalogued data layer Sermorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Sermorelin's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Hexarelin

Phase 2 (not approved)

Sermorelin

Discontinued (FDA approval 1990; US withdrawal 2008)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Hexarelin Sermorelin
Class GHRP; potent ghrelin receptor agonist GHRH analog
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism GHS-R1a agonist; more potent GH release than other GHRPs Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release
Route SC / Intranasal SC injection
Half-life ~1 hr ~10-20 min
Dosage (research) 100-200 mcg SC 1-2x daily (short cycles) 200-500 mcg SC at bedtime daily
Evidence tier Phase 2 (not approved) Discontinued (FDA approval 1990; US withdrawal 2008)
Research depth 158 indexed (PubMed 141 · CT 0 · EPMC 17) 149 indexed (PubMed 122 · CT 17 · EPMC 10)
Availability Research Chemical Compounding Restricted
Reported risks Cortisol/prolactin elevation; pituitary desensitization Injection site reactions; headache; flushing

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Hexarelin or Sermorelin?

Hexarelin and Sermorelin share the gh-secretagogue class and carry roughly equivalent evidence (Phase 2 (not approved) / Discontinued (FDA approval 1990; US withdrawal 2008)). On the catalogued data layer Sermorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Sermorelin's evidence base is currently denser.

What is the difference between Hexarelin and Sermorelin?

Hexarelin is classed as GHRP; potent ghrelin receptor agonist; Sermorelin is classed as GHRH analog. Reported mechanism: Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs; Sermorelin, Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release. Reported half-life: Hexarelin, ~1 hr; Sermorelin, ~10-20 min. Routes in published studies: Hexarelin, SC / Intranasal; Sermorelin, SC injection.

Which has stronger evidence, Hexarelin or Sermorelin?

Hexarelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 158 indexed studies. Sermorelin is graded Discontinued (FDA approval 1990; US withdrawal 2008), with 6 cited sources on its reference page and 149 indexed studies.

Which is more accessible, Hexarelin or Sermorelin?

Neither Hexarelin nor Sermorelin is an FDA-approved drug. Catalog status: Hexarelin, Research Chemical; Sermorelin, Compounding Restricted.

Are Hexarelin and Sermorelin ever combined?

Hexarelin and Sermorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…